1Lee KY. Pediatric respiratory infections by Mycoplasma pneumonia [J]. Expert Rev Anti Infect Ther,2008,6(3) :509-521.
2Chen ZR, Yan YD, Wang YQ, et al. Epidemiology of community-ac- quired Mycoplasma Pneumoniae respiratory tract infections among hospitalized Chinese children, including relationships with meteore- logical[J]. Hir, vokratia.2013.17 ( 1 ) :20-26.
8Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections [ J ]. Expert Opin Investig Drugs ,2009,17 ( 3 ) :387-400.
6Shimizu T, Kida Y, Kuwano K from Mycoplasma pneumoniae Triacylated lipoproteins derived activate nuclear factor-kappaB through toll-like receptors 1 and 2 [ J ]. Immunology, 2007, 121 (4) :473-483.
7Romero-Rojas A, Ponce-Herndndez C, Cipridn A, et al. Immu- nomodulatory properties of Mycoplasma pulmonis. I. Characteriza- tion of the immunomodulatory activity[J]. Int Immunopharmacol, 2001,1 ( 9-10 ) : 1679-1688.
8Dumke R, Schurwanz N, Lenz M, et al. Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by op- timized real-time PCR approach [ J ]. J Clin Microbiol, 2007, 45 ( 8 ) :2726-2730.
9Shimizu T, Kida Y, Kuwano K. Mycoplasma pneumoniae-derived lipopeptides induce acute inflammatory responses in the lungs of mice[ J]. Infect Immun, 2008,76( 1 ) :270-277.
10Attilakos A, Palaiologou P, Lagona E, et al. Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin [ J ]. Pediatr Neurol, 2008,38(5) :357-359.
